During this segment, Maria Lopes, MD, MS, explains that cost is not the only factor that is associated with treatment nonadherence in patients with diabetes and obesity. Dr Lopes notes that cost is usually number 3 on the list of reasons why patients do not take medicine as prescribed.
Dr Lopes explains that nonadherence is multifactorial; other factors that contribute to nonadherence include the development of troublesome side effects, denial of the disease diagnosis, healthcare disparities, and psychosocial issues including depression. She notes the importance of individualized treatment.
Yehuda Handelsman, MD, FACP, FACE, FNLA, discusses the relationship between adherence and overall outcomes. He explains that poor adherence rates have been associated with poor outcomes for patients in several disease categories including diabetes.
Dr Handelsman emphasizes the need to improve patient adherence and highlights the results of a published study that determined that 33% of patients never visit the pharmacy to fill a prescription.
To address patient nonadherence issues, Dr Lopes believes that regardless of treatment response or the success rates of pharmacotherapy options, patients need to receive continued support from healthcare professionals.
Kari Uusinarkaus, MD, FAAFP, FNLA, further explains how health literacy is related to adherence, and suggests that physicians need to speak to patients on a level that patients can understand.
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
USPSTF Lowers Age for Biennial Mammograms to 40, Citing Early Detection Benefit
April 30th 2024The USPSTF lowered the recommended starting age for mammograms from 50 to 40 years, citing moderate benefits for early detection in this age group. Disparities persist, especially for Black women, highlighting the need for improved access to health care and social support.
Read More
Makers of medical tests will have about 4 years to show the FDA that their new offerings deliver accurate results; after previously decreasing for 27 years, US tuberculosis (TB) cases increased every year since 2020; a US district judge rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to the Medicare drug price negotiation program.
Read More
2 Commerce Drive
Cranbury, NJ 08512